Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma in Children, Adolescents, and Young Adults-Reference-Cited by-同舟云学术

Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma in Children, Adolescents, and Young Adults

Published:2024-07 Issue:5 Volume:22 Page:
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Gardenswartz Aliza¹,Cairo Mitchell S.¹²³⁴⁵

Affiliation:

1. Department of Pediatrics, New York Medical College, Valhalla, NY

2. Department of Pathology, New York Medical College, Valhalla, NY

3. Department of Medicine, New York Medical College, Valhalla, NY

4. Department of Microbiology and Immunology, New York Medical College, Valhalla, NY

5. Department of Cell Biology and Anatomy, New York Medical College, Valhalla, NY

Abstract

Despite excellent cure rates among children, adolescents, and young adults (CAYAs) with mature B-cell non-Hodgkin lymphomas (B-NHLs) treated with chemoimmunotherapy, CAYAs with relapsed/refractory B-NHL remain difficult to treat, with a dismal prognosis. Reinduction and subsequent therapeutic management are not standardized. The armamentarium of active agents against B-NHL, including antibody–drug conjugates, monoclonal antibodies, checkpoint inhibitors, T-cell engagers, CAR T cells, CAR-natural killer (CAR-NK) cells, and cell signaling inhibitors, continues to expand. This article reviews current management practices and novel therapies in this difficult to treat population.

Publisher

Harborside Press, LLC

Link

https://jnccn.org/downloadpdf/journals/jnccn/22/5/article-e247006.xml

Reference80 articles.

1. Novel therapies potentially available for pediatric B-cell non-Hodgkin lymphoma;Harker-Murray PD,2020

2. Mature B-NHL in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies;Egan G,2019

3. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents;Cairo MS,2007

4. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB LMB 96 study;Cairo MS,2012

5. Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy;Gerrard M,2013